Is ARX a Buy? What to Consider in 2026
Short answer
The bull case for Accelerant Holdings (ARX) rests on Growing the exchange network: Accelerant's core lever is adding MGA members and risk capital partners, then taking a volume-based fee on the premium that flows between them. Revenue (FY 2025 / Q1 2026) is ~$913 million FY 2025; ~$273 million in Q1 2026 (up ~54%). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The dominant uncertainty is that the capital-light model is young and unproven across a full insurance cycle. Whether ARX is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Accelerant Holdings operates a data-driven risk exchange for specialty insurance. On one side are managing general agents (MGAs), the specialist underwriters who design and sell niche insurance products; on the other are risk capital partners such as insurers, reinsurers, and institutional investors who put up the capital to back those policies. Accelerant sits in the middle, using proprietary technology, data, and machine learning to match risk with capital, share high-fidelity underwriting data, and monitor portfolios. It earns a fixed-percentage, volume-based fee for sourcing, managing, and monitoring the business written through the exchange, which spans more than 500 specialty insurance products across 22 countries. The company reports through three segments: Exchange Services, MGA Operations, and Underwriting, and describes its model as capital-light because it aims to retain only a small share of the premium risk (roughly 9% in 2025) and pass the rest to third-party capital. In 2025 the exchange handled about $4.19 billion of Exchange Written Premium, up roughly 35% year over year, with revenue rising about 51% to $913 million and adjusted EBITDA up sharply to $282 million. The headline figure was a $1.35 billion net loss, but that stemmed almost entirely from a $1.38 billion non-cash profits interest distribution tied to the IPO rather than from operations. Accelerant listed its Class A shares on the NYSE under ARX on July 24, 2025, raising about $724 million. Momentum carried into 2026: first-quarter revenue rose about 54% year over year to roughly $273 million with adjusted EBITDA up about 69%, and management raised full-year guidance, targeting revenue near $1.02 billion for 2026.
What's the case for buying ARX?
1. Growing the exchange network
Accelerant's core lever is adding MGA members and risk capital partners, then taking a volume-based fee on the premium that flows between them. It reported strong MGA member additions and high net revenue retention in early 2026, which suggests existing members are writing more through the platform. More participants and deeper usage compound the fee base without Accelerant having to carry the underlying risk.
2. The capital-light shift
The company is steering more premium to third-party capital and retaining less on its own balance sheet (around 9% of premium in 2025). If that shift holds, revenue becomes more fee-like and less dependent on Accelerant's own capital, which management frames as a path to surplus capital and more durable free cash flow. It also lowers the amount of underwriting loss the company absorbs directly.
3. Operating leverage on a technology platform
Because the exchange is software and data rather than a branch-heavy carrier, revenue can scale faster than costs. Adjusted EBITDA grew far faster than premium and revenue in 2025 (up roughly 149%) and again in the first quarter of 2026 (up about 69%). If that leverage continues, incremental premium flowing through the exchange should convert to profit at a high rate.
4. International and product breadth
Accelerant already supports more than 500 specialty products across 22 countries, giving it many niches to expand into rather than one concentrated line. It is also rolling out hybrid structures that pair MGAs with capital more flexibly. Breadth across geographies and products can smooth results, though each new market and product adds operational and regulatory complexity.
What are the risks to ARX?
The dominant uncertainty is that the capital-light model is young and unproven across a full insurance cycle. Accelerant still reported a large net loss in 2025, and while it was driven by a one-time non-cash IPO item, the gap between statutory results and adjusted metrics means the reported economics deserve scrutiny. As a marketplace, the business depends on keeping both MGAs and capital partners engaged; if capital providers pull back after a run of claims or if competing carriers and fronting platforms court its MGAs, volumes and fees could suffer. Specialty insurance is inherently cyclical, and a soft pricing market or a spike in catastrophe or liability losses could reduce premium flow and pressure the small share of risk Accelerant does retain. The stock is also newly public with a short trading history and a valuation that already embeds continued rapid growth, so disappointments can move it sharply.
How is ARX valued? (as of July 2026)
Snapshot for ARX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Exchange Written Premium (FY 2025): ~$4.19 billion, up ~35% year over year
- Revenue (FY 2025 / Q1 2026): ~$913 million FY 2025; ~$273 million in Q1 2026 (up ~54%)
- Adjusted EBITDA: ~$282 million FY 2025; ~$66 million in Q1 2026 (up ~69%)
- Net income (FY 2025): ~$1.35 billion loss, almost all from a ~$1.38 billion non-cash IPO item
- Market cap: ~$3.0 billion (stock ~$13 per share)
- Valuation: ~9x forward (FY 2026) EV/EBITDA
Figures are approximate and tied to the asOf date; verify live numbers before acting. Because Accelerant only listed in July 2025, its trading and reporting history is short, and its large statutory net loss diverges from the adjusted EBITDA it emphasizes, so the two frames tell different stories. The valuation reflects rapid revenue and EBITDA growth rather than current bottom-line profit, meaning the figures matter most as a gauge of how much future growth is already priced in.
How do you decide if ARX is a buy?
Rather than asking whether ARX is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ARX indirectly through an index or sector ETF before adding more.
For the full picture, see the ARX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ARX against your real portfolio and see your actual exposure before deciding.
The bottom line on ARX
The bottom line: Accelerant Holdings's story right now is Growing the exchange network, with revenue (fy 2025 / q1 2026) at ~$913 million FY 2025; ~$273 million in Q1 2026 (up ~54%). If you believe that narrative continues, the call is about sizing ARX sensibly and checking overlap with what you own; if you doubt it (the risk: the dominant uncertainty is that the capital-light model is young and unproven across a full insurance cycle.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ARX with Walnut
Use Accelerant Holdings as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ARX a good stock to buy right now?
+
The case for Accelerant Holdings right now is Growing the exchange network, with revenue (fy 2025 / q1 2026) at ~$913 million FY 2025; ~$273 million in Q1 2026 (up ~54%). If you believe that thesis holds, ARX is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the dominant uncertainty is that the capital-light model is young and unproven across a full insurance cycle. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Accelerant Holdings do?
+
Accelerant Holdings operates a data-driven risk exchange for specialty insurance.
What are the main risks of ARX?
+
The dominant uncertainty is that the capital-light model is young and unproven across a full insurance cycle. Accelerant still reported a large net loss in 2025, and while it was driven by a one-time non-cash IPO item, the gap between statutory results and adjusted metrics means the reported economics deserve scrutiny. As a marketplace, the business depends on keeping both MGAs and capital partners engaged; if capital providers pull back after a run of claims or if competing carriers and fronting platforms court its MGAs, volumes and fees could suffer. Specialty insurance is inherently cyclical, and a soft pricing market or a spike in catastrophe or liability losses could reduce premium flow and pressure the small share of risk Accelerant does retain. The stock is also newly public with a short trading history and a valuation that already embeds continued rapid growth, so disappointments can move it sharply.
What does Accelerant Holdings (ARX) do?
+
Accelerant runs a technology-driven risk exchange for specialty insurance. It connects managing general agents (MGAs), the specialists who design and sell niche insurance products, with risk capital partners such as insurers, reinsurers, and institutional investors who fund the policies. Accelerant uses data and machine learning to match risk with capital and earns a volume-based fee on the premium that flows through its platform, across more than 500 products in 22 countries.
Is ARX a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is rapid growth in exchange premium and revenue, a capital-light fee model, and strong operating leverage. The bear case is a short public history, a large reported net loss, an unproven model across a full insurance cycle, and a valuation that already assumes continued fast growth. Weigh both against your own portfolio.
When did Accelerant Holdings go public?
+
Accelerant listed its Class A common shares on the New York Stock Exchange under the ticker ARX on July 24, 2025, raising roughly $724 million in the IPO. Because it is a recent listing, the stock has a short trading history and limited quarters of public financial reporting, which is worth keeping in mind when assessing its track record.
Why did Accelerant report a $1.35 billion loss in 2025?
+
The 2025 net loss of about $1.35 billion came almost entirely from a roughly $1.38 billion non-cash profits interest distribution tied to the IPO, not from ongoing operations. On an operating basis the company grew adjusted EBITDA to about $282 million. The gap between the reported loss and adjusted metrics is why it helps to look at both figures rather than the headline number alone.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ARX; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.